微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 27.61% | -1.65% | 0.47% | 119/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 27.48% | 5.53% | -3.44% | 119/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 28.46% | 0.5% | -0.06% | 119/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 28.48% | 9.85% | 1.43% | 120/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 28.08% | 8% | 7.81% | 121/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 26.04% | 0.07% | -8.05% | 122/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 28.32% | 3.33% | 9.25% | 121/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 25.93% | -4.82% | -0.28% | 125/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 26% | -8.12% | -0.11% | 124/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 26.02% | -14% | -5.05% | 124/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 27.41% | 0.48% | 0.63% | 123/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 27.24% | -7.18% | -3.73% | 123/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 28.29% | -7.19% | -6.5% | 123/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 30.26% | 2.44% | 10.94% | 117/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.28% | -3.42% | -7.04% | 125/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.34% | -6.11% | -3.75% | 114/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 30.49% | -2.91% | 3.2% | 115/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 29.54% | -5.43% | 4.59% | 114/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 28.24% | -17.45% | -9.63% | 129/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.25% | -17.07% | -0.47% | 109/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 31.4% | -20.58% | 0.52% | 119/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 31.24% | -22.74% | -8.7% | 103/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 34.21% | -0.62% | -9.22% | 118/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.69% | 9.3% | -4.67% | 94/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 39.53% | 12.16% | -2.22% | 97/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 40.43% | 10.6% | 17.43% | 81/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 34.43% | 10.68% | -0.15% | 110/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 34.48% | 10.32% | -2.18% | 88/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.25% | 10.45% | -3.58% | 91/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.56% | 2% | 17.51% | 80/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 31.11% | -10.96% | -0.48% | 112/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 31.26% | 2% | -2.06% | 84/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 31.91% | -14.12% | -8.65% | 85/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 34.94% | -13.15% | -5.99% | 89/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-06-30 | 37.16% | 2% | -7.62% | 71/157 | 47.91% | 贝达药业 | 95.74% | 行业排名> |
| 2016-12-31 | 40.22% | 25.36% | 25.36% | 67/157 | 48.46% | 退市金泰 | 96.19% | 行业排名> |